Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off on Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.
Alex Wasyl, CEO Nexien BioPharma

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Alex Wasyl, CEO Nexien BioPharma

 

 

 

 

 

 

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.




Related Articles

Newsmakers

Yield Growth (OTC: BOSQF) Furthers Position in $22-billion Hemp and CBD Industry with Appointment of Specialist New York Agency The Design Spot for Urban Juve and Mad Wallaby for Marketing

April 7, 2019 admin Newsmakers Comments Off on Yield Growth (OTC: BOSQF) Furthers Position in $22-billion Hemp and CBD Industry with Appointment of Specialist New York Agency The Design Spot for Urban Juve and Mad Wallaby for Marketing

Beauty and Wellness Experience for Successful Global Brands, Creativity, and Strategic Acumen Determined the Successful Agency Selection VANCOUVER, British Columbia, April 04, 2019 – The Yield Growth Corp. (CSE: BOSS) (OTC: BOSQF) (frankfurt:YG3) announces The Design […]

Healthcare

CytoDyn (OTC: CYDY) to Present at RHK Capital 2019 Disruptive Growth Conference

August 29, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) to Present at RHK Capital 2019 Disruptive Growth Conference

VANCOUVER, Washington, Aug. 29, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]